etrasimod vs ozanimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
etrasimod · Velsipity
Marketed by Pfizer and partners
NCT03945188 · Phase 3 · completed
Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.
Next expected readout: June 2027 · NCT07782242 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Clinical Remission at Week 12; Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) (met)
Result source: NCT03945188
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb and partners
NCT02435992 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.
Next expected readout: July 2032 · NCT05076175 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)
Result source: NCT02435992
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | etrasimod | ozanimod |
|---|---|---|
| Clinical remission (induction) | 27% vs 7.4%+19.6 vs placeboNCT039451886 other results
| 18.4% vs 6%+12.4 vs placeboNCT024359923 other results
|
| Clinical remission (maintenance) | 32.1% vs 6.7%+25.4 vs placeboNCT039451883 other results
| 37% vs 18.5%+18.5 vs placeboNCT024359922 other results
|
| Clinical response (induction) | 62.4% vs 34.1%+28.3 vs placeboNCT039451886 other results
| 47.8% vs 25.9%+21.9 vs placeboNCT024359923 other results
|
| Endoscopic improvement (induction) | 35% vs 14.1%+20.9 vs placeboNCT039451886 other results
| 27.3% vs 11.6%+15.7 vs placeboNCT024359923 other results
|
| Corticosteroid-free remission (maintenance) | 32.1% vs 6.7%+25.4 vs placeboNCT039451886 other results
| 31.7% vs 16.7%+15 vs placeboNCT02435992 |
Clinical remission (induction)
- etrasimod
- 27% vs 7.4%+19.6 vs placeboNCT03945188
6 other results
- 24.8% vs 15.2% NCT03996369
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
- 33% vs 8.1% NCT02447302
- 16% vs 8.1% NCT02447302
- 28.3% vs 11.7% NCT04607837
- ozanimod
- 18.4% vs 6%+12.4 vs placeboNCT02435992
3 other results
- 21% vs 6% NCT02435992
- 16.4% vs 6.2% NCT01647516
- 13.8% vs 6.2% NCT01647516
Clinical remission (maintenance)
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
3 other results
- 25% vs 7.1% NCT04706793
- 49.1% vs 17.4% NCT03945188
- 26% vs 18.3% NCT04607837
- ozanimod
- 37% vs 18.5%+18.5 vs placeboNCT02435992
2 other results
- 20.9% vs 6.2% NCT01647516
- 26.2% vs 6.2% NCT01647516
Clinical response (induction)
- etrasimod
- 62.4% vs 34.1%+28.3 vs placeboNCT03945188
6 other results
- 62.2% vs 41.1% NCT03996369
- 50.6% vs 32.5% NCT02447302
- 43.7% vs 32.5% NCT02447302
- 55.9% vs 36.7% NCT04607837
- 52.6% vs 7.1% NCT05061446
- 33.3% vs 7.1% NCT05061446
- ozanimod
- 47.8% vs 25.9%+21.9 vs placeboNCT02435992
3 other results
- 52.6% vs 25.9% NCT02435992
- 56.7% vs 36.9% NCT01647516
- 53.8% vs 36.9% NCT01647516
Endoscopic improvement (induction)
- etrasimod
- 35% vs 14.1%+20.9 vs placeboNCT03945188
6 other results
- 30.6% vs 18.8% NCT03996369
- 41.8% vs 17.8% NCT02447302
- 22.5% vs 17.8% NCT02447302
- 44.1% vs 20% NCT04607837
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
- ozanimod
- 27.3% vs 11.6%+15.7 vs placeboNCT02435992
3 other results
- 27.2% vs 11.6% NCT02435992
- 34.3% vs 12.3% NCT01647516
- 27.7% vs 12.3% NCT01647516
Corticosteroid-free remission (maintenance)
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
6 other results
- 31% vs 7.5% NCT03945188
- 25% vs 7.1% NCT04706793
- 25.2% vs 16.7% NCT04607837
- 25.2% vs 16.7% NCT04607837
- 16.2% vs 16.7% NCT04607837
- 30% vs 30% NCT04607837
- ozanimod
- 31.7% vs 16.7%+15 vs placeboNCT02435992
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. etrasimod: 11 of 11 rows · ozanimod: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | etrasimod Rows use multiple source trials | ozanimod Rows use multiple source trials |
|---|---|---|
| Clinical Remission responder rate · % of participants Extension (open-label) | 39.3% (n=84) vs 25% (n=4) placebo @ 46wk2 mga,b,c NCT02536404 · Phase 2 · registry result, not featured evidence | 44% (n=266) vs 41.6% (n=113) placebo @ 46wka,b,c NCT02531126 · Phase 3 · monotherapy |
| Clinical Response responder rate · % of participants Maintenance | 48.2% (n=274) vs 23% (n=135) placebo @ 52wk2 mgb NCT03945188 · Phase 3 · monotherapy 1 other source trial44.1% (n=127) vs 38.3% (n=60) placebo @ 52wk NCT04607837 · Phase 2 · registry result, not featured evidence | 60% (n=230) vs 39.1% (n=69) placebo @ 52wkb NCT02435992 · Phase 3 · monotherapy |
| Clinical Response responder rate · % of participants Extension (open-label) | 78.6% (n=84) vs 75% (n=4) placebo @ 46wk2 mga,b,c NCT02536404 · Phase 2 · registry result, not featured evidence | 77% (n=261) vs 81.8% (n=110) placebo @ 46wka,b,c NCT02531126 · Phase 3 · monotherapy |
| Endoscopic Improvement responder rate · % of participants Maintenance | 37.2% (n=274) vs 10.4% (n=135) placebo @ 52wk2 mgb NCT03945188 · Phase 3 · monotherapy 1 other source trial32.3% (n=127) vs 23.3% (n=60) placebo @ 52wk NCT04607837 · Phase 2 · registry result, not featured evidence | 45.7% (n=230) vs 29% (n=69) placebo @ 52wkb NCT02435992 · Phase 3 · monotherapy |
| Mucosal Healing responder rate · % of participants Induction | 21.2% (n=274) vs 4.4% (n=135) placebo @ 12wk2 mgb,d NCT03945188 · Phase 3 · monotherapy 3 other source trials16.2% (n=222) vs 8.9% (n=112) placebo @ 12wk2 mg NCT03996369 · Phase 3 · monotherapy 6.7% (n=15) vs 0% (n=14) placebo @ 12wk1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 5.3% (n=19) vs 0% (n=14) placebo @ 12wk2 mg NCT05061446 · Phase 2 · registry result, not featured evidence | 12.6% (n=429) vs 3.7% (n=216) placebo @ 10wke,b,d NCT02435992 · Phase 3 · monotherapy show 1 more dose11.4% (n=367) vs 3.7% (n=216) placebo @ 10wk NCT02435992 · Phase 3 · monotherapy |
| Mucosal Healing responder rate · % of participants Maintenance | 26.6% (n=274) vs 8.1% (n=135) placebo @ 52wk2 mgb NCT03945188 · Phase 3 · monotherapy | 29.6% (n=230) vs 10.1% (n=69) placebo @ 52wkb NCT02435992 · Phase 3 · monotherapy |
| Total Mayo absolute change · score Induction | -3.35 vs -2.08 placebo score @ 12wk2 mge,b,c,f NCT02447302 · Phase 2 · registry result, not featured evidence show 1 more dose-2.69 vs -2.08 placebo score @ 12wk1 mg NCT02447302 · Phase 2 · registry result, not featured evidence | -3.4 vs -2 placebo score @ 8wk1 mge,b,c,f NCT01647516 · Phase 2 · registry result, not featured evidence show 1 more dose-2.6 vs -2 placebo score @ 8wk0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 44.3%2 mgg NCT03945188 · Phase 3 · monotherapy show 8 more results10.5%2 mg NCT03996369 · Phase 3 · monotherapy 35.7%2 mg NCT04706793 · Phase 3 · monotherapy 37.4% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 5.9%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 17.9%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 8%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 9.6%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence | —1mgg NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 11.7%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 46.3%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 69.5%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 4.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.5%2 mgg NCT03945188 · Phase 3 · monotherapy show 8 more results3.8%2 mg NCT03996369 · Phase 3 · monotherapy —2 mg NCT04706793 · Phase 3 · monotherapy 5.2% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 4.5%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 6%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 7.7%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence | —1mgg NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 3.3%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 7.4%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 6.1%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 3%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.9%2 mgg NCT03945188 · Phase 3 · monotherapy show 8 more results2.5%2 mg NCT03996369 · Phase 3 · monotherapy 3.6%2 mg NCT04706793 · Phase 3 · monotherapy 6.5% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 6.3%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 0%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 5.8%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence | 4%1mgg NCT02435992 · Phase 3 · monotherapy show 15 more results6.3%1mg NCT02435992 · Phase 3 · monotherapy 5.2%1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy —RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 14.8%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 17.2%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy 3%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 2.4%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 18.6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 1.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 25%0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 9.1%Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 2 mgg anaemia 8.3% (placebo 9.7%) headache 8.3% (placebo 4.9%) covid-19 6.6% (placebo 5.6%) NCT03945188 · Phase 3 · monotherapy show 8 more results2 mg anaemia 5.9% (placebo 6.9%) headache 4.6% (placebo 1.7%) nausea 4.2% (placebo 1.7%) NCT03996369 · Phase 3 · monotherapy 2 mg headache 14.3% (placebo 14.3%) malaise 10.7% (placebo 0%) pyrexia 10.7% (placebo 14.3%) NCT04706793 · Phase 3 · monotherapy colitis ulcerative 12.3% (placebo 10.1%) covid-19 9.7% (placebo 8.9%) alanine aminotransferase increased 8.4% (placebo 1.3%) NCT04607837 · Phase 2 · registry result, not featured evidence 2 mg alanine aminotransferase increased 5.3% (placebo 0%) back pain 5.3% (placebo 0%) blood creatine phosphokinase increased 5.3% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 1 mg stomatitis 11.8% (placebo 0%) anaemia 5.9% (placebo 0%) cataract 5.9% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 2 mg colitis ulcerative 14.3% (placebo 16.7%) anaemia 8.9% (placebo 0%) gamma-glutamyltransferase increased 8.9% (placebo 0%) NCT02536404 · Phase 2 · registry result, not featured evidence 2 mg anaemia 6% (placebo 3.7%) headache 6% (placebo 1.9%) colitis ulcerative 4% (placebo 1.9%) NCT02447302 · Phase 2 · registry result, not featured evidence 1 mg upper respiratory tract infection 7.7% (placebo 3.7%) colitis ulcerative 5.8% (placebo 1.9%) anaemia 3.8% (placebo 3.7%) NCT02447302 · Phase 2 · registry result, not featured evidence | show 11 more resultscovid-19 25.9% (placebo 16.8%) lymphopenia 16.7% (placebo 17.3%) leukopenia 7.4% (placebo 4.1%) NCT02531126 · Phase 3 · monotherapy lymphopenia 16.3% (placebo 17.3%) covid-19 11.3% (placebo 16.8%) lymphocyte count decreased 10.8% (placebo 12.8%) NCT02531126 · Phase 3 · monotherapy 1 mg alanine aminotransferase increased 3% (placebo 0%) headache 3% (placebo 4.6%) anaemia 1.5% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg alanine aminotransferase increased 2.4% (placebo 0%) colitis ulcerative 2.4% (placebo 1.5%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg hypertension 11.9% (placebo 0%) gamma-glutamyltransferase increased 8.5% (placebo 0%) upper respiratory tract infection 8.5% (placebo 3.1%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg anaemia 6.2% (placebo 6.2%) colitis ulcerative 3.1% (placebo 1.5%) back pain 1.5% (placebo 1.5%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg alanine aminotransferase increased 2.8% (placebo 0%) nasopharyngitis 2.8% (placebo 0%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg/1 mg anaemia 5.4% (placebo 6.2%) gamma-glutamyltransferase increased 5.4% (placebo 0%) lymphocyte count decreased 5.4% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence anaemia 7.3% (placebo 6.2%) colitis ulcerative 7.3% (placebo 1.5%) bronchitis 5.5% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 12 weeks versus 10 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 12 weeks versus 8 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
etrasimod
show 19 more results
show 2 more results
show 4 more results
show 16 more results
show 10 more results
show 14 more results
show 3 more results
show 1 more result
+ 3 further endpoints in the CSV export.
ozanimod
show 9 more results
show 4 more results
show 9 more results
show 9 more results
show 6 more results
show 7 more results
show 6 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etrasimod's landscape · ozanimod's landscape